AxoGen (NASDAQ:AXGN) Price Target Raised to $56.00

Key Points

• Wells Fargo raised AxoGen’s price target to $56 from $48 and maintained an “overweight” rating, implying approximately 14.4% upside from the previous close.
• AxoGen reported quarterly adjusted EPS of $0.21 versus the $0.13 consensus estimate, while revenue reached $75.83 million, exceeding expectations. Management also raised its 2026 revenue outlook to at least $290 million, representing minimum growth of 29%.
• Analyst sentiment remains favorable, with 12 Buy ratings and a consensus “Moderate Buy” rating; the average price target is $56.27. However, the company continues to post negative net margins and return on equity.

AxoGen (NASDAQ:AXGN - Get Free Report) had its price target raised by equities research analysts at Wells Fargo & Company from $48.00 to $56.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the medical equipment provider's stock. Wells Fargo & Company's target price indicates a potential upside of 14.40% from the stock's previous close.

A number of other research analysts have also recently issued reports on AXGN. Bank of America began coverage on shares of AxoGen in a research note on Monday, October 12th. They issued a "buy" rating and a $52.00 price objective on the stock. Wall Street Zen downgraded AxoGen from a "buy" rating to a "hold" rating in a report on Saturday, September 26th. Barclays reiterated an "overweight" rating and issued a $60.00 price target on shares of AxoGen in a research note on Thursday. Lake Street Capital reissued a "buy" rating on shares of AxoGen in a research note on Monday, October 5th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $60.00 price target on shares of AxoGen in a research note on Wednesday. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, AxoGen presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.27.

AxoGen Price Performance

AxoGen stock traded down $0.30 during trading hours on Thursday, reaching $48.95. 131,550 shares of the stock were exchanged, compared to its average volume of 1,191,204. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07. AxoGen has a twelve month low of $21.68 and a twelve month high of $52.91. The company has a market cap of $2.63 billion, a P/E ratio of -71.68 and a beta of 1.17. The stock has a 50 day moving average of $42.78 and a two-hundred day moving average of $39.28.

AxoGen (NASDAQ:AXGN - Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, beating the consensus estimate of $0.13 by $0.08. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The company had revenue of $75.83 million during the quarter, compared to analysts' expectations of $73.18 million. Equities analysts expect that AxoGen will post -0.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Kathy Weiler sold 14,150 shares of the company's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Wendell sold 13,353 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the sale, the director directly owned 107,976 shares of the company's stock, valued at $5,228,197.92. This represents a 11.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,503 shares of company stock valued at $4,656,947 over the last 90 days. 2.44% of the stock is owned by company insiders.

Hedge Funds Weigh In On AxoGen

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of AxoGen during the 2nd quarter worth approximately $204,123,000. Artemis Investment Management LLP lifted its position in AxoGen by 27.5% in the 3rd quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider's stock valued at $74,659,000 after acquiring an additional 384,200 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of AxoGen by 44.3% during the second quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider's stock valued at $64,280,000 after buying an additional 427,089 shares during the last quarter. Bamco Inc. NY purchased a new stake in shares of AxoGen in the second quarter valued at about $34,190,000. Finally, TimesSquare Capital Management LLC bought a new stake in AxoGen in the 2nd quarter worth about $31,863,000. 80.29% of the stock is owned by institutional investors and hedge funds.

Key AxoGen News

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. AxoGen reported adjusted earnings of $0.21 per share, versus the $0.13–$0.14 consensus range, while revenue increased to $75.83 million from an expected $73.18 million. Earnings also improved from $0.12 per share a year earlier. AxoGen Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Management raised 2026 revenue guidance. AxoGen now expects full-year revenue of at least $290 million, representing minimum growth of 29%. The higher outlook signals continued demand for its peripheral nerve repair products and was a key catalyst for investor enthusiasm. AxoGen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: HC Wainwright raised its price target to $56 from $53 and maintained a Buy rating. The revised target implies additional upside from the reported $49.25 reference price and reinforces the improving analyst view of AXGN’s growth prospects. HC Wainwright stock recommendations
• Positive Sentiment: Options activity reflected strong speculative interest. Investors purchased 9,886 call options, compared with average daily call volume of about 900, suggesting increased bullish positioning after the earnings release.
• Neutral Sentiment: Despite the earnings beat, AxoGen continues to report a negative net margin and negative return on equity. Its elevated valuation following the rally could also limit further gains unless revenue growth and profitability continue to improve. Does AxoGen Have More Upside?

About AxoGen

AxoGen, Inc NASDAQ: AXGN is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company's product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient's body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.